Pulseless ventricular tachycardia medical therapy: Difference between revisions
Jump to navigation
Jump to search
Aisha Adigun (talk | contribs) |
Aisha Adigun (talk | contribs) |
||
| Line 6: | Line 6: | ||
==Medical Therapy== | ==Medical Therapy== | ||
*Medical therapy with IV vasopressors and antiarrhythmic medications is usually simultaneous with defibrillation. | *Medical therapy with IV [[vasopressors]] and [[antiarrhythmic medications]] is usually simultaneous with [[defibrillation]]. | ||
*Antiarrhythmic drugs can be attempted in pulseless ventricular tachycardia that is resistant to shock. Intravenous amiodarone is the first line in this scenario, lidocaine may be considered as well. 2018 AHA recommendations for use of antiarrhythmic drugs during resuscitation from adult VF/pVT cardiac arrest state that both medications may be especially useful on patients with witnessed arrest, for whom time to drug administration may be shorter. | *Antiarrhythmic drugs can be attempted in [[pulseless ventricular tachycardia]] that is resistant to shock. Intravenous [[amiodarone]] is the first line in this scenario, [[lidocaine]] may be considered as well. 2018 AHA recommendations for use of antiarrhythmic drugs during [[resuscitation]] from adult VF/pVT cardiac arrest state that both medications may be especially useful on patients with witnessed arrest, for whom time to drug administration may be shorter. | ||
*1mg 1V of epinephrine administered every 3-5 minutes or, a single dose of 40 units IV of vasopressin can be used as vasopressors.<ref name="pmid23196774">{{cite journal |vauthors=Callaway CW |title=Epinephrine for cardiac arrest |journal=Curr. Opin. Cardiol. |volume=28 |issue=1 |pages=36–42 |date=January 2013 |pmid=23196774 |doi=10.1097/HCO.0b013e32835b0979 |url=}}</ref> | *1mg 1V of [[epinephrine]] administered every 3-5 minutes or, a single dose of 40 units IV of vasopressin can be used as vasopressors.<ref name="pmid23196774">{{cite journal |vauthors=Callaway CW |title=Epinephrine for cardiac arrest |journal=Curr. Opin. Cardiol. |volume=28 |issue=1 |pages=36–42 |date=January 2013 |pmid=23196774 |doi=10.1097/HCO.0b013e32835b0979 |url=}}</ref> | ||
==References== | ==References== | ||
Revision as of 00:36, 10 July 2020
|
Pulseless ventricular tachycardia Microchapters |
|
Differentiating Pulseless ventricular tachycardia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Pulseless ventricular tachycardia medical therapy On the Web |
|
American Roentgen Ray Society Images of Pulseless ventricular tachycardia medical therapy |
|
Pulseless ventricular tachycardia medical therapy in the news |
|
Risk calculators and risk factors for Pulseless ventricular tachycardia medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aisha Adigun, B.Sc., M.D.[2]
Overview
Medical Therapy
- Medical therapy with IV vasopressors and antiarrhythmic medications is usually simultaneous with defibrillation.
- Antiarrhythmic drugs can be attempted in pulseless ventricular tachycardia that is resistant to shock. Intravenous amiodarone is the first line in this scenario, lidocaine may be considered as well. 2018 AHA recommendations for use of antiarrhythmic drugs during resuscitation from adult VF/pVT cardiac arrest state that both medications may be especially useful on patients with witnessed arrest, for whom time to drug administration may be shorter.
- 1mg 1V of epinephrine administered every 3-5 minutes or, a single dose of 40 units IV of vasopressin can be used as vasopressors.[1]
References
- ↑ Callaway CW (January 2013). "Epinephrine for cardiac arrest". Curr. Opin. Cardiol. 28 (1): 36–42. doi:10.1097/HCO.0b013e32835b0979. PMID 23196774.